Search company, investor...

DHC Group

About DHC Group

DHC Group funds and conducts research, hosts, and produces industry events, and offers media and outreach opportunities for its members. The company conducts strategic research projects on a range of topics related to digital pharmaceutical marketing innovation. Survey results, white paper analysis, and key takeaways. The company is based in Brooklyn, New York.

Headquarters Location

195 Montague Street

Brooklyn, New York, 11201,

United States

Missing: DHC Group's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: DHC Group's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest DHC Group News

98% of Pharmaceutical Executives Agree on Importance of Omnichannel as Half of Companies Are Not Optimizing Physician Engagement across Touchpoints, Study Finds

Dec 6, 2022

December 06, 2022 07:00 AM Eastern Standard Time SAN FRANCISCO--( BUSINESS WIRE )-- Aktana , the leader in intelligent customer engagement for the global life sciences industry, today reveals striking results from a new study, “The State of Omnichannel HCP Engagement in Pharma: Where the Industry Stands in 2022.” In DHC Group’s survey of 50 industry executives across digital, brand marketing, field sales, and data analytics, 98% found omnichannel strategy to be “very important” while more than half of these companies say they are not yet optimizing HCP engagement across touchpoints. The gap suggests commercial models are changing, but gradually. “After decades of a go-to-market approach defined by best-guess strategies and appealing to physicians as a monolithic group, we’re finally flipping the script,” said Derek Choy, president of Aktana. “Today, it’s a strategic imperative for brands to transform the HCP experience into a seamless, cross-channel journey that’s personalized to a segment of one. With so many more options for engagement, organizations also need a scalable way to prioritize actions with the highest impact, refine strategies and focus valuable resources where they’ll deliver the greatest ROI. None of this is possible without AI.” Survey respondents indicated a few key challenges to omnichannel success. These include: Data and Technology Integration – 45% attributed challenges to complexities integrating and managing data People, Structure & Culture – 54% noted the inability to influence change management Enough Content – content continues to be a significant hurdle in brand marketing as 62% of respondents say they lack personalized content Single Platform Aligned with KPIs – nearly two-thirds report an unmet need for a single interface to manage and control omnichannel engagement across the organization Aktana’s modular solution enables commercial and medical teams from all-sized organizations to rapidly scale AI programs to personalize, optimize, and coordinate HCP engagement across channels and teams – allowing customers to grow sales by up to 15%. It has more than 300 deployments across 50+ use cases. More than half of the world's top-20 pharmaceutical companies – including Novartis, GSK, Novo Nordisk, Merck, Sanofi, and Pfizer – rely on Aktana to coordinate and optimize personalized omnichannel engagement with HCPs. Aktana’s Contextual Intelligence 360 platform is powered by the company’s next-generation Contextual Intelligence Engine , which uses AI-driven optimization to predict the value of all potential customer experiences, then prioritize and recommend Next Best Engagements. “In three to five years, I would hope that we've suddenly moved as an industry where AI isn't a buzzword. It's actually just baked into the mainstream of our go-to-market strategies because it's so essential,” said Novartis’ Global Director of Field Force AI Enablement Paul Thompson in the DHC report. In other news, Aktana was named a trailblazer in Everest Group’s assessment report, “ Life Sciences Commercial Analytics & AI Trailblazers. " The report assessed 47 startups primarily on core capabilities and market impact, looking specifically at domain focus, market buzz, product capabilities, and human capital (talent and leadership). Aktana received the highest overall rating. For a complete copy of the DHC Group study and to understand organizational readiness for omnichannel, please contact Lisa Barbadora ( ) or click here . Additional Information:

DHC Group Frequently Asked Questions (FAQ)

  • Where is DHC Group's headquarters?

    DHC Group's headquarters is located at 195 Montague Street, Brooklyn.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.